China Likely To Delay Drug Price Cuts Until Next Year: Good News Or Bad?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The National Development and Reform Commission, China's leading economic regulatory body, is revising a drug price control plan that was issued in June for public feedback after receiving industry-led objections to some proposals
You may also be interested in...
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies
Will China Healthcare Reform Drive Higher Rewards For Innovative Drugs?
BEIJING - China's sweeping healthcare reforms - designed to provide universal coverage for more than 1.3 billion citizens and build or upgrade medical care facilities across the country - are likely to have staggered benefits on varying industries over the next decade